463 completed, 189 unknown, 118 recruiting, 94 terminated. 989 Phase 3, 162 Phase 2.
Follow Colonic Diseases: new trials by email Literature Review of Colonic Diseases trials Research Report on Colonic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis Nitazoxanide (NTZ) - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Not yet recruiting | Tanta University | 44 | 2027-01-01 | 2026-09-15 |
| Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders Rifaximin (drug), Placebo - Bloating, Rifaximin | Phase 3 | Not yet recruiting | Mahidol University | 78 | 2026-12-01 | 2026-10-27 |
| Effects of Butyrate Enemas on Postoperative Intestinal Motility Disorders in Hirschsprung's Disease Sodium Butyrate, routine management - Hirschsprung's Disease | Phase 3 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 58 | 2026-11-01 | 2026-09-10 |
| Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC Rilogrotug, Placebo - Cachexia; Cancer, Cachexia | Phase 2 / Phase 3 | Not yet recruiting | AVEO Pharmaceuticals, Inc. | 950 | 2026-11-01 | 2026-10-28 |
| GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer GFH375 + Cetuximab, Fruquintinib, Trifluridine and Tipiracil - Colorectal Cancer | Phase 3 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 368 | 2026-11-01 | 2026-11-03 |
| Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS short-course radiotherapy, Serplulimab, CapOx(Capecitabine+ Oxaliplatin) - Locally Advanced Colon Cancer, pMMR | Phase 3 | Not yet recruiting | Fudan University | 480 | 2026-10-15 | 2026-10-16 |
| Fruquintinib Combined With Capecitabine as Adjuvant Extended Therapy After R0 Resection and Perioperative Chemotherapy in Patients With Liver-Only Metastatic Colorectal Cancer Fruquintinib Combined With Capecitabine, Follow-up observation - Colorectal Cancer | Phase 3 | Not yet recruiting | West China Hospital | 140 | 2026-10-08 | 2026-10-21 |
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) Petosemtamab, Cetuximab, Bevacizumab - Colorectal Cancer | Phase 3 | Recruiting | Genmab | 600 | 2026-10-07 | 2026-11-03 |
| Preventive Dendritic Cell Vaccination for Lynch Syndrome Carriers Arm A: DC vaccination, Arm B: Placebo vaccination - Lynch Syndrome | Phase 3 | Not yet recruiting | Radboud University Medical Center | 372 | 2026-10-01 | 2026-05-27 |
| Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) - Colorectal Cancer, Gastric Cancers | Phase 2 / Phase 3 | Recruiting | GE Healthcare | 175 | 2026-10-01 | 2026-06-17 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients FOLFIRI+cetuximab, Guardant360 ctDNA assay - Colorectal Cancer Metastatic | Phase 3 | Not yet recruiting | Charite University, Berlin, Germany | 267 | 2026-10-01 | 2026-07-29 |
| Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis Ponesimod, Placebo - Ulcerative Colitis (UC) | Phase 3 | Recruiting | Vanda Pharmaceuticals | 150 | 2026-09-01 | 2026-08-18 |
| Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa, Placebo - Colorectal Cancer | Phase 3 | Recruiting | Exelixis | 600 | 2026-08-25 | 2026-09-21 |
| Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With Cancer Vedolizumab, Placebo - IrAE, Immune-related Adverse Event | Phase 2 / Phase 3 | Recruiting | AHS Cancer Control Alberta | 36 | 2026-08-13 | 2026-08-27 |
| Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial) Modafinil, Placebo - Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Chronic Fatigue | Phase 2 / Phase 3 | Recruiting | Radboud University Medical Center | 60 | 2026-08-03 | 2026-09-14 |
| A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer OncoVAX and Surgery, Surgery - Stage II Colon Cancer | Phase 3 | Not yet recruiting | Vaccinogen Inc | 550 | 2026-08-01 | 2026-02-02 |
| A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan BL-M07D1, Regorafenib, Fruquintinib - Colorectal Cancer | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 130 | 2026-08-01 | 2026-08-27 |
| IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer IBI363 + bevacizumab, Investigator's choice of therapy - Colorectal Cancer | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 550 | 2026-07-31 | 2026-08-10 |
| FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC FOLFIRI + bevacizumab + QL1706, FOLFIRI + bevacizumab - Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC) | Phase 3 | Not yet recruiting | Sun Yat-sen University | 270 | 2026-07-30 | 2026-07-27 |
Showing 20 of 989. Sign in to see all of them.
Colorectal Neoplasms (520) · Colonic Neoplasms (237) · Colitis, Ulcerative (223) · Rectal Neoplasms (125) · Irritable Bowel Syndrome (71) · Neoplasm Metastasis (52) · Inflammatory Bowel Diseases (49) · Crohn Disease (35) · Neoplasms (34) · Colitis (20) · Diarrhea (20) · Gastrointestinal Diseases (20) · Intestinal Diseases (19) · Breast Neoplasms (16)
Digestive System Diseases (973) · Intestinal Diseases (970) · Gastrointestinal Diseases (969) · Neoplasms by Site (658) · Intestinal Neoplasms (656) · Digestive System Neoplasms (655) · Gastrointestinal Neoplasms (652) · Neoplasms (634) · Rectal Diseases (541) · Gastroenteritis (242) · Colitis (220) · Inflammatory Bowel Diseases (186) · Pathological Conditions, Signs and Symptoms (161) · Colorectal Neoplasms (145)
Fluorouracil (166) · Leucovorin (159) · Oxaliplatin (130) · Bevacizumab (110) · Irinotecan (89) · Capecitabine (83) · Cetuximab (58) · Folfox protocol (48) · Mesalamine (42) · Panitumumab (21) · regorafenib (20) · Chemotherapy, Adjuvant (18) · Drug Therapy (18) · trifluridine tipiracil drug combination (17) · vedolizumab (16)
Sun Yat-sen University (24) · Janssen Research & Development, LLC (20) · Alliance for Clinical Trials in Oncology (19) · Fudan University (19) · Hoffmann-La Roche (19) · Bausch Health Americas, Inc. (15) · Pfizer (15) · AbbVie (14) · National Cancer Institute (NCI) (14) · Amgen (11) · Eli Lilly and Company (11) · Merck Sharp & Dohme LLC (11) · Takeda (11) · NSABP Foundation Inc (10) · Sanofi (10)
United States (326) · China (196) · France (190) · Germany (187) · Canada (178) · Italy (170) · United Kingdom (170) · Belgium (161) · Spain (152) · Poland (144) · Netherlands (131) · South Korea (127) · Australia (123) · Japan (120) · Hungary (112)
Norman Wolmark, MD (9) · Aimery de Gramont, MD (5) · Alfredo Falcone, MD (4)
PMID 36306483, PMID 31268130, PMID 32445184, PMID 33356421, PMID 30679026, PMID 31378656, PMID 21997132, PMID 29850873, PMID 30476584, PMID 31077827, PMID 31599001, PMID 32085892, PMID 32766762, PMID 32816215, PMID 32870265, PMID 32964215, PMID 33324993, PMID 33684552, PMID 34614208, PMID 35648151, PMID 35792493, PMID 36124702, PMID 36336750, PMID 36342120, PMID 36526796, PMID 36931693, PMID 37402275, PMID 37560161, PMID 38310565, PMID 38425446, PMID 40013523, PMID 26049686, PMID 26563167, PMID 27959607, PMID 28467869, PMID 29028981, PMID 29142515, PMID 29380251, PMID 29409871, PMID 29627309, PMID 29743836, PMID 29909019, PMID 30739254, PMID 31279870, PMID 31982148, PMID 33127596, PMID 33439695, PMID 33513294, PMID 34035832, PMID 34077627
2023 (25), 2017 (15), 2015 (13), 2025 (13), 2016 (11), 2018 (10), 2019 (7), U10CA031946 (7), 2014 (6), 2004 (5), U10CA012027 (5), 2009 (4), U10CA032102 (4), 2008 (3), U10CA021115 (3)